Advertisement

Topics

Hemispherx Biopharma initiated with a Buy rating and $8 price target at Maxim

08:30 EDT 14 Jun 2019 | Proactive Investors

Analyst Jason McCarthy says that with a $10M valuation and potentially positive data expected over 2019 and 2020, there’s plenty of upside

Original Article: Hemispherx Biopharma initiated with a Buy rating and $8 price target at Maxim

NEXT ARTICLE

More From BioPortfolio on "Hemispherx Biopharma initiated with a Buy rating and $8 price target at Maxim"

Advertisement
Quick Search
Advertisement
Advertisement